GeneDx Holdings Corporation (WGS)

GeneDx to Participate in the Goldman Sachs 47th Annual Global Healthcare ConferenceMay 26, 2026 4:05 PM
Business Wire GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced that company management will participate in the Goldman Sachs 47th Annual Global Healthcare Conference from June 8-10 in Miami, FL. Management will participate in a fireside chat on Tuesday, June 9, 2026, at 8:00 a.m. ET. A live and archived webcast of the presentation will be available on the “Events” section of the GeneDx investor relations website at ir.genedx.com/news-events/events. About GeneDx
GeneDx’s (Nasdaq: WGS) mission is to empower everyone to live their healthiest life through genomics. GeneDx combines unmatched clinical expertise, advanced technology, and the power of GeneDx Infinity™ – the world’s largest rare disease genomic dataset. This unparalleled foundation powers GeneDx’s ExomeDx™ and GenomeDx® tests – ranked #1 by expert geneticists and granted FDA Breakthrough Device designation – enabling clinicians to deliver precise, fast, and actionable diagnoses. GeneDx Infinity™ also fuels discovery for biopharma, with the most powerful AI-driven genomic intelligence. A genomics pioneer over the last 25 years, diagnosing more than 4,800 genetic diseases and publishing more than 1,000 research publications, GeneDx is building the network that will drive the future of genomic precision medicine. For more information, visit genedx.com and connect with us on LinkedIn, Facebook, and Instagram. View source version on businesswire.com: https://www.businesswire.com/news/home/20260526880629/en/ Investor Relations Contact:
Investors@GeneDx.com Media Contact:
Press@GeneDx.com Original: GeneDx to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

GeneDx Reports First Quarter 2026 Financial Results and Updates Full-Year OutlookMay 4, 2026 4:05 PM
Business Wire Reported total revenue of $102.3 million with 27% year-over-year growth in exome and genome revenue Reported exome and genome volume growth of 34% year-over-year Reported adjusted gross margin(1) of 69% and adjusted net loss(1) of $8.2 million Updating full-year 2026 revenue guidance to $475 to $490 million with exome and genome volume growth of at least 30% Hosting conference call today at 4:30 p.m. ET GeneDx Holdings Corp. (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today reported its financial results for the first quarter of 2026. “GeneDx delivered 34% year-over-year volume growth in exome and genome testing in the first quarter – a clear signal that there’s sustained, strong demand for our services. While our revenue did not reflect the full potential of what this business is capable of, we are adjusting our outlook and are poised to deliver more than 30% volume growth, 70% gross margin, and profitability on an adjusted basis for the year,” said Katherine Stueland, CEO of GeneDx. “Leading a generational shift in medicine requires taking some big swings, learning quickly, and moving with urgency to serve this ever-growing patient population. With expectations reset, we’ve never been more confident about our ability to deliver profitable growth in service of patients and shareholders.” First Quarter 2026 Financial Results (Unaudited)(1) Revenue Revenue grew to $102.3 million, an increase of 17% year-over-year. Exome and genome test revenue grew to $90.6 million, an increase of 27% year-over-year. Exome and genome volume Exome and genome test result volume grew to 27,488, an increase of 34% year-over-year. Gross margin Adjusted gross margin remained flat at 69% in the first quarter of 2026. GAAP gross margin was 67%. Operating expenses Adjusted total operating expenses were $78.1 million, representing 76% of revenue. Total GAAP operating expenses were $94.4 million. Net (loss) income Adjusted net loss was $8.2 million compared to adjusted net income of $9.2 million in the first quarter of 2025. GAAP net loss was $63.3 million. Cash position Cash, cash equivalents, marketable securities and restricted cash was $171.7 million as of March 31, 2026. (1)   Adjusted gross margin, adjusted total operating expenses and adjusted net (loss) income are non-GAAP financial measures. See appendix for a reconciliation of GAAP to non-GAAP figures presented. Updated 2026 Guidance GeneDx has updated its 2026 guidance. Management now expects GeneDx to deliver: Metric   Full Year 2026 Previous Guidance   Full Year 2026 Updated Guidance   Second Quarter of 2026 Guidance Revenue   $540 to $555 million   $475 to $490 million   $110 to $112 million Growth in exome and genome volume   33% to 35%   At least 30%   Approximately 30,000 tests Growth in exome and genome revenue   33% to 35%   At least 20%   Approximately $100 million Adjusted gross margin   At least 70%   Approximately 70%   Approximately 70% Adjusted net income (loss)   Positive   Positive   Adj. net loss of approximately $5 million First Quarter 2026 and Recent Business Highlights Strategic Expansion and Market Leadership Announced the landmark SAVES-Kids Study, a real-world data Health Economics and Outcomes Research (HEOR) study showing an average healthcare cost savings of up to $80,000 for children with neurodevelopmental disorders in the 12 months following ExomeDx™ and GenomeDx™ testing, regardless of the test result. Launched a reflex product, enabling seamless reflexing to genome testing when exome testing is non-diagnostic. Partnered with CNBC to launch CNBC Cures, a collaborative, multi-platform initiative aimed at raising awareness for the rare disease community and improving outcomes for the ~30 million Americans affected by rare diseases. Launched a sponsored genetic testing program with Zevra Therapeutics to support patients with suspected Niemann-Pick Disease Type C. Expanded Medicaid coverage in Texas, Maine, and Arkansas, resulting in approximately 4.9 million Medicaid patients gaining access to exome testing. Innovation & Clinical Leadership Added to the company’s more than 1,100 publications by showcasing 18 pieces of pioneering research at the American College of Medical Genetics and Genomics (ACMG) Annual Meeting. The research highlighted the scale and clinical impact of GeneDx Infinity™ – the largest and most comprehensive rare disease genomic dataset – and GeneDx’s leadership in bringing exome and genome testing to the standard of care by leveraging AI, world-class data and clinical expertise, and expert variant interpretation and classification. Published results from a benchmarking study in the American Journal of Human Genetics demonstrating HiFi long-read sequencing was successful in identifying difficult to detect variants using real-world clinical samples. Published new SeqFirst study data in the American Journal of Medical Genetics showing that implementing rapid genome sequencing (rWGS) as a first-tier test in pediatric and cardiac intensive care units significantly increases diagnostic rates and reduces time to diagnosis by 50%. Presented “Scaling Rare Disease Discovery with AI: From Genomic Data to Therapeutic Insights” at the Precision Medicine Worldwide Conference (PMWC), showcasing how GeneDx partners with biopharma to turn genomic data into actionable solutions – accelerating discovery, enabling clinical trials, and advancing the next era of precision medicine. Webcast and Conference Call Details GeneDx will host a conference call today, May 4, 2026, at 4:30 p.m. Eastern Time. Investors interested in listening to the conference call are required to register online. A live and archived webcast of the event will be available on the “Events” section of the GeneDx investor relations website at https://ir.genedx.com/. Non-GAAP Financial Measures GeneDx believes non-GAAP measures are useful in evaluating its operating performance. GeneDx uses this supplemental information to evaluate its ongoing operations and for internal planning and forecasting purposes. GeneDx believes that non-GAAP financial information, when taken collectively with its GAAP financial information, may be helpful to investors because it provides consistency and comparability with past financial performance. However, non-GAAP financial information is presented for supplemental informational purposes only, has limitations as an analytical tool, and should not be considered in isolation or as a substitute for financial information presented in accordance with GAAP. Reconciliations of non-GAAP financial measures to the most directly comparable financial results as determined in accordance with GAAP are included at the end of this press release following the accompanying financial data. We define non-GAAP financial measures as GAAP measures, excluding certain items such as stock-based compensation expense, depreciation and amortization, restructuring costs, changes in the fair value of financial liabilities, non-core lease costs, and other expenses that the Company believes are not indicative of its ongoing operations. A reconciliation of non-GAAP guidance measures to corresponding GAAP measures is not available on a forward-looking basis without unreasonable effort due to the uncertainty of expenses that may be incurred in the future. Investors are encouraged to review the related GAAP financial measures and the reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measures and not rely on any single financial measure to evaluate our business. Forward-Looking Statements This press release contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995, including statements regarding our future performance and our market opportunity, including our expectations for full year and second quarter 2026 revenue, exome and genome revenue and test volumes, adjusted gross margin and adjusted net income (loss). These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: (i) our ability to implement business plans, goals and forecasts, and identify and realize additional opportunities, (ii) the risk of downturns and a changing regulatory landscape in the highly competitive healthcare industry, (iii) the size and growth of the market in which we operate, and (iv) recalibrating for building long-term, durable performance. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the U.S. Securities and Exchange Commission (the “SEC”) on February 23, 2026, our Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2026, filed with the SEC on May 4, 2026 and other documents filed by us from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and we assume no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. We do not give any assurance that we will achieve our expectations. About GeneDx GeneDx’s (Nasdaq: WGS) mission is to empower everyone to live their healthiest life through genomics. GeneDx combines unmatched clinical expertise, advanced technology, and the power of GeneDx Infinity™ – the world’s largest rare disease genomic dataset. This unparalleled foundation powers GeneDx’s ExomeDx™ and GenomeDx™ tests – ranked #1 by expert geneticists and granted FDA Breakthrough Device designation – enabling clinicians to deliver precise, fast, and actionable diagnoses. GeneDx Infinity also fuels discovery for biopharma, with the most powerful AI-driven genomic intelligence. A genomics pioneer over the last 25 years, diagnosing more than 4,800 genetic diseases and publishing more than 1,100 research publications, GeneDx is building the network that will drive the future of genomic precision medicine. For more information, visit genedx.com and connect with us on LinkedIn, Facebook, and Instagram. Volume & Revenue     1Q26     4Q25     3Q25     2Q25     1Q25 Volumes                   Whole exome, whole genome   27,488     27,761     25,702     23,246     20,562 Hereditary cancer   108     346     1,511     2,677     2,725 Other panels   27,621     30,935     33,003     31,833     28,228 Total   55,217     59,042     60,216     57,756     51,515                     Revenue ($ millions)                   Whole exome, whole genome $ 90.6   $ 104.0   $ 98.9   $ 86.0   $ 71.4 Hereditary cancer   0.1     0.2     1.2     1.8     2.2 Other panels   10.6     13.1     13.4     12.3     12.1 Data information   0.8     2.6     1.5     2.0     1.4 Software and interpretation services   0.2     1.1     1.7     0.6     — Total $ 102.3   $ 121.0   $ 116.7   $ 102.7   $ 87.1 Unaudited Select Financial Information (in thousands)   Three months ended March 31, 2026   Three months ended March 31, 2025   GeneDx   Other(1)   Total   GeneDx   Other(1)   Total Revenue $101,496   $758   $102,254   $87,115   $—   $87,115 Adjusted cost of services 31,613   588   32,201   27,396   —   27,396 Adjusted gross profit $69,883   $170   $70,053   $59,719   $—   $59,719 Adjusted gross margin % 68.9%       68.5%   68.6%       68.6% (1) For the three months ended March 31, 2026, Other represents revenues and cost of services from the Fabric Genomics operating segment. For the three months ended March 31, 2025, Other represents revenues and cost of services from the Legacy Sema4 diagnostic testing business.   Three months ended March 31, 2026   Reported   Depreciation and amortization   Stock-based compensation   Restructuring costs   Change in FV of financial liabilities   Extinguishment of debt   Other(2)   Adjusted Diagnostic test revenue $ 101,299     $ —     $ —     $ —     $ —     $ —   $ —     $ 101,299   Other revenue   955       —       —       —       —       —     —       955   Total revenue   102,254       —       —       —       —       —     —       102,254   Cost of services   34,043       (1,462 )     (380 )     —       —       —     —       32,201   Gross profit   68,211       1,462       380       —       —       —     —       70,053   Gross margin   66.7 %                             68.5 % Research and development   19,804       (224 )     (1,406 )     (224 )     —       —     —       17,950   Selling, general and administrative   74,591       (5,123 )     (7,210 )     (215 )     —       —     (1,916 )     60,127   Impairment loss   31,287       —       —       —       —       —     (31,287 )     —   Loss from operations   (57,471 )     6,809       8,996       439       —       —     33,203       (8,024 )                                 Interest expense, net   (717 )     —       —       —       —       —     717       —   Other (expense) income, net   (4,231 )     —       —       —       (2,540 )     6,565     —       (206 ) Income tax expense   (897 )     —       —       —       —       —     897       —   Net loss $ (63,316 )   $ 6,809     $ 8,996     $ 439     $ (2,540 )   $ 6,565   $ 34,817     $ (8,230 )                                 Basic and diluted loss per share(1) $ (2.16 )                           $ (0.28 )   Three months ended March 31, 2025   Reported   Depreciation and amortization   Stock-based compensation   Restructuring costs   Change in FV of financial liabilities   Other(2)   Adjusted Diagnostic test revenue $ 85,759     $ —     $ —     $ —     $ —       $ 85,759   Other revenue   1,356       —       —       —       —     —       1,356   Total revenue   87,115       —       —       —       —     —       87,115   Cost of services   28,639       (1,075 )     (168 )     —       —     —       27,396   Gross profit   58,476       1,075       168       —       —     —       59,719   Gross margin   67.1 %                         68.6 % Research and development   12,577       (372 )     (419 )     (28 )     —     —       11,758   Selling, general and administrative   50,450       (4,231 )     (3,396 )     (530 )     —     (3,265 )     39,028   (Loss) income from operations   (4,551 )     5,678       3,983       558       —     3,265       8,933                               Interest expense, net   (640 )     —       —       —       —     640       —   Other (expense) income, net   (891 )     —       —       —       1,100     30       239   Income tax expense   (447 )     —       —       —       —     447       —   Net (loss) income $ (6,529 )   $ 5,678     $ 3,983     $ 558     $ 1,100   $ 4,382     $ 9,172                               Basic (loss) earnings per share(1) $ (0.23 )                       $ 0.33   Diluted (loss) earnings per share(1) $ (0.23 )                       $ 0.31   (1)   Basic and diluted (loss) earnings per share are calculated based on 29,335,126 weighted average shares outstanding for the three months ended March 31, 2026, and 28,147,948 and 29,440,704 weighted average shares outstanding for the three months ended March 31, 2025, respectively. (2)   Other represents interest expense, net, income tax expense and non-core lease costs for all periods presented. For the three months ended March 31, 2026, Other also includes costs related to legal reserves and impairment of goodwill and intangible assets associated with the Fabric Genomics acquisition. For the three months ended March 31, 2025, Other includes transaction costs incurred in connection with the acquisition of Fabric Genomics. GeneDx Holdings Corp. Condensed Consolidated Balance Sheets (in thousands, except share and per share amounts)     March 31, 2026 (Unaudited)   December 31, 2025 Assets:       Current assets:       Cash and cash equivalents $ 93,924     $ 104,997   Marketable securities   76,761       66,285   Accounts receivable   76,929       74,370   Inventory, net   12,241       13,951   Prepaid expenses and other current assets   10,774       8,685   Total current assets   270,629       268,288   Operating lease right-of-use assets   34,653       23,412   Property and equipment, net   50,125       45,693   Goodwill   1,641       13,520   Intangible assets, net   144,969       168,481   Other assets(1)   4,284       4,316   Total assets $ 506,301     $ 523,710   Liabilities and Stockholders’ Equity:       Current liabilities:       Accounts payable and accrued expenses $ 46,562     $ 57,645   Short-term lease liabilities   5,129       4,404   Other current liabilities   35,948       46,859   Total current liabilities   87,639       108,908   Long-term debt, net of current portion   96,732       48,176   Long-term lease liabilities   66,331       56,046   Other liabilities   71       1,641   Deferred taxes   1,404       757   Total liabilities   252,177       215,528   Stockholders’ Equity:       Preferred stock   —       —   Class A common stock   3       3   Additional paid-in capital   1,690,249       1,680,738   Accumulated deficit   (1,436,811 )     (1,373,495 ) Accumulated other comprehensive income   683       936   Total stockholders’ equity   254,124       308,182   Total liabilities and stockholders’ equity $ 506,301     $ 523,710   (1) Other assets includes $1.0 million of restricted cash as of both March 31, 2026 and December 31, 2025. GeneDx Holdings Corp. Condensed Consolidated Statements of Operations (Unaudited) (in thousands, except share and per share amounts)     Three months ended March 31,     2026       2025   Revenue       Diagnostic test revenue $ 101,299     $ 85,759   Other revenue   955       1,356   Total revenue   102,254       87,115   Cost of services   34,043       28,639   Gross profit   68,211       58,476   Research and development   19,804       12,577   Selling, general and administrative   74,591       50,450   Impairment loss   31,287       —   Loss from operations   (57,471 )     (4,551 )         Non-operating (expenses) income, net       Change in fair value of financial liabilities   2,540       (1,100 ) Interest expense, net   (717 )     (640 ) Loss on extinguishment of debt   (6,565 )     —   Other (expense) income, net   (206 )     209   Total non-operating expense, net   (4,948 )     (1,531 ) Loss before income taxes   (62,419 )     (6,082 ) Income tax expense   (897 )     (447 ) Net loss $ (63,316 )   $ (6,529 )         Weighted-average shares outstanding of Class A common stock   29,335,126       28,147,948   Basic and diluted loss per share, Class A common stock $ (2.16 )   $ (0.23 ) GeneDx Holdings Corp. Condensed Consolidated Statements of Cash Flows (Unaudited) (in thousands)     Three months ended March 31,     2026       2025   Operating activities       Net loss $ (63,316 )   $ (6,529 ) Adjustments to reconcile net loss to net cash (used in) provided by operating activities:       Depreciation and amortization expense   6,809       5,678   Stock-based compensation expense   8,996       3,983   Change in fair value of financial liabilities   (2,540 )     1,100   Deferred tax expense   897       447   Change in third party payor reserves   1,022       1,395   Loss on extinguishment of debt   6,565       —   Impairment loss   31,287       —   Other   1,034       757   Change in operating assets and liabilities:       Accounts receivable   (2,558 )     (8,557 ) Inventory   1,689       (2,032 ) Accounts payable and accrued expenses   (13,168 )     10,824   Other assets and liabilities   (9,125 )     3,116   Net cash (used in) provided by operating activities   (32,408 )     10,182   Investing activities       Purchases of marketable securities   (20,177 )     (17,209 ) Proceeds from sales of marketable securities   875       —   Proceeds from maturities of marketable securities   8,500       13,930   Purchases of property and equipment and development of internal-use software   (6,453 )     (6,129 ) Net cash used in investing activities   (17,255 )     (9,408 ) Financing activities       Proceeds from long term debt, net of issuance costs   96,998       13,894   Proceeds from issuance of common stock from subscription agreements   476       —   Exercise of stock options   58       735   Repayment of long-term debt, including prepayment penalty - Perceptive   (54,000 )     —   Repayment and principal payments for long-term debt - DECD   (4,447 )     (300 ) Finance lease principal payments   (495 )     (611 ) Net cash provided by financing activities   38,590       13,718   Net (decrease) increase in cash, cash equivalents and restricted cash   (11,073 )     14,492   Cash, cash equivalents and restricted cash, at beginning of period   105,989       86,202   Cash, cash equivalents and restricted cash, at end of period (1) $ 94,916     $ 100,694           Supplemental disclosures of cash flow information       Cash paid for interest $ 1,748     $ 1,600   Cash paid for taxes $ 754     $ 206   Lease liability from obtaining right-of-use asset $ 12,086     $ —   Purchases of property and equipment in accounts payable and accrued expenses $ 5,915     $ 2,197   (1) Cash, cash equivalents and restricted cash as of March 31, 2026 excludes marketable securities of $76.8 million.   View source version on businesswire.com: https://www.businesswire.com/news/home/20260504673812/en/ Investor Relations Contact:
Investors@GeneDx.com Media Contact:
Press@GeneDx.com Original: GeneDx Reports First Quarter 2026 Financial Results and Updates Full-Year Outlook

GeneDx to Report First Quarter 2026 Financial Results on Monday, May 4, 2026April 13, 2026 4:05 PM
Business Wire
GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced it will release financial results for the first quarter of 2026 after the market closes on Monday, May 4, 2026. Management will host a conference call that day to discuss first quarter 2026 financial and operating results at 4:30 p.m. Eastern Time.


Conference Call Details


Investors interested in listening to the conference call are required to register online. A live and archived webcast of the event will be available on the “Events” section of the GeneDx investor relations website at https://ir.genedx.com/.


About GeneDx


GeneDx’s (Nasdaq: WGS) mission is to empower everyone to live their healthiest life through genomics. GeneDx combines unmatched clinical expertise, advanced technology, and the power of GeneDx Infinity™ – the world’s largest rare disease genomic dataset. This unparalleled foundation powers GeneDx’s ExomeDx™ and GenomeDx™ tests – ranked #1 by expert geneticists and granted FDA Breakthrough Device designation – enabling clinicians to deliver precise, fast, and actionable diagnoses. GeneDx Infinity also fuels discovery for biopharma, with the most powerful AI-driven genomic intelligence. A genomics pioneer over the last 25 years, diagnosing more than 4,800 genetic diseases and publishing more than 1,000 research publications, GeneDx is building the network that will drive the future of genomic precision medicine. For more information, visit genedx.com and connect with us on LinkedIn, Facebook, and Instagram.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260413990348/en/
Investor Relations Contact:

Investors@GeneDx.com
Media Contact:

Press@GeneDx.com


Original: GeneDx to Report First Quarter 2026 Financial Results on Monday, May 4, 2026

Landmark Study Shows Average Cost Savings of $80,000 Per Child and Overall Improved Health Outcomes Following GeneDx Exome and Genome TestingMarch 11, 2026 5:00 PM
Business Wire
New data shows up to 61% reduction in healthcare costs for children with neurodevelopmental disorders in the 12 months following ExomeDx™ and GenomeDx™ testing, regardless of the test result


GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced findings from the Genetic Sequencing Analysis has Value in Economic Savings (SAVES)-Kids Study, a real-world data Health Economics and Outcomes Research (HEOR) analysis led by GeneDx that focuses on the economic impact of whole exome sequencing (WES) and whole genome sequencing (WGS) in children with neurodevelopmental disorders, like epilepsy and developmental delay and intellectual disability (DD/ID). The data was unveiled today at the American College of Medical Genetics and Genomics (ACMG) Annual Meeting in Baltimore, MD.


The study demonstrates that GeneDx’s ExomeDx™ and GenomeDx™ significantly reduce total healthcare costs in the 12- and 24-months following testing for patients covered by private insurance and Medicaid.



Savings were primarily driven by fewer hospitalizations and reduced emergency room utilization – patterns consistent with accurate diagnoses and more targeted, high-value care after genomic testing.



Additionally, the study found that all test result types (positive, possible, and negative) offer significant average cost savings and improved health outcomes.



“This data makes one thing undeniable – early exome and genome testing changes the trajectory of care regardless of test result,” said Katherine Stueland, President and CEO of GeneDx. “For years, GeneDx has known that faster access to exome and genome sequencing shortens the diagnostic odyssey and drives more precise clinical action. Now we have clear, real-world evidence showing it also reduces avoidable hospitalizations, lowers emergency room utilization, and meaningfully decreases total healthcare spend – particularly in Medicaid populations where every dollar and every moment matters.”


For children presenting with epilepsy:



Average total healthcare costs decreased 61% from $130,048 per patient per year (PPPY) in the years leading up to GeneDx WES/WGS to $50,798 PPPY in the 12 months following testing



Average reduction in healthcare costs of $79,250 PPPY



Reduced hospitalization costs were the largest contributor to these savings



Children with epilepsy covered by Medicaid showcased similar meaningful first-year economic and utilization improvements:



Average reduction of total healthcare costs of 53% in the year after WES/WGS compared to the year prior to testing, translating to approximately $50,000 in total healthcare cost savings



Savings were the result of substantial declines in acute care utilization, with 80% fewer hospitalizations and 70% fewer emergency room visits in the year directly after testing



Decrease in high-cost acute care was coupled with a moderate increase in outpatient and pharmacy costs, suggesting that healthcare resources were being better directed



Children with DD/ID demonstrated the same trends in healthcare resource utilization and average cost savings:



Total healthcare costs were reduced by 19%, representing approximately $9,000 in total healthcare cost savings in the first-year post-exome or genome testing



Significant reductions in acute care utilization, with 80% fewer hospitalizations and 50% fewer emergency room visits



While outpatient costs increased by 38% and pharmacy costs increased by 37%, overall healthcare costs for patients with DD/ID declined



This shift is consistent with better directed outpatient management and ongoing therapy care decisions informed by the WES/WGS test result



Despite clinical guidelines supporting WES/WGS as a first-tier test, children with neurological disorders often are not tested when the onset of symptoms, like seizures, first begin. The SAVES-Kids HEOR study adds real-world evidence that WES/WGS may help accelerate the transition from episodic, high-cost acute care to more planned outpatient and therapeutic pathways, underscoring the opportunity for health systems to realize greater value when exome and genome testing are implemented earlier in alignment with medical guidelines.


“Exome and genome sequencing deliver better health outcomes and measurable cost savings. The standard of care must reflect that reality,” said Linda Genen, MD, MPH, FAAP, Chief Medical Officer at GeneDx. “The earlier genomic testing is implemented, the faster children receive targeted management, and the more efficiently health systems and payors can allocate resources. The data is clear – genomic precision medicine is not just better care, it is smarter healthcare.”


As the leader in rare disease diagnosis, GeneDx delivers the #1 genetic test and is the top choice of pediatric and genetic providers nationwide. GeneDx has delivered more rare disease diagnoses than any other organization in the world – a distinction made possible by GeneDx Infinity™, the world’s largest rare disease dataset of more than one million exomes and genomes and over 2.5 million tests. By combining patient insights from Komodo Health's Healthcare Map® with data from GeneDx Infinity, GeneDx is uniquely positioned to help shape a smarter, more proactive healthcare system – improving outcomes for families across the country.


About GeneDx

GeneDx’s (Nasdaq: WGS) mission is to empower everyone to live their healthiest life through genomics. GeneDx combines unmatched clinical expertise, advanced technology, and the power of GeneDx Infinity™ – the world’s largest rare disease genomic dataset. This unparalleled foundation powers GeneDx’s ExomeDx™ and GenomeDx™ tests – ranked #1 by expert geneticists and granted FDA Breakthrough Device designation – enabling clinicians to deliver precise, fast, and actionable diagnoses. GeneDx Infinity also fuels discovery for biopharma, with the most powerful AI-driven genomic intelligence. A genomics pioneer over the last 25 years, diagnosing more than 4,800 genetic diseases and publishing more than 1,000 research publications, GeneDx is building the network that will drive the future of genomic precision medicine. For more information, visit genedx.com and connect with us on LinkedIn, Facebook, and Instagram.


Forward Looking Statements


This press release may contain “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: (i) our ability to advance gene-disease discovery and implement plans to accelerate and unlock the full potential of precision medicine, (ii) the risk of downturns and a changing regulatory landscape in the highly competitive healthcare industry, (iii) the size and growth of the market in which we operate, (iv) our ability to pursue our new strategic direction. The foregoing list of factors is not exhaustive. A further list and description of risks, uncertainties and other matters can be found in the “Risk Factors” section of our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, and other documents filed by us from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and we assume no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. We do not give any assurance that we will achieve our expectations.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260311695167/en/
Investor Relations Contact:

Investors@GeneDx.com


Media Contact:

Press@GeneDx.com


Original: Landmark Study Shows Average Cost Savings of $80,000 Per Child and Overall Improved Health Outcomes Following GeneDx Exome and Genome Testing

GeneDx Posts Mixed Q4 Performance as Earnings Miss but Revenue Tops EstimatesFebruary 23, 2026 8:32 AM
IH Market News
GeneDx Holdings Corp. (NASDAQ:WGS) reported mixed results for the fourth quarter, with earnings falling short of expectations even as revenue came in slightly ahead of analyst forecasts.Shares slipped 0.07% in pre-market trading following the release.The rare disease diagnostics firm reported a quarterly loss of $0.61 per share, well below the analyst consensus, which had projected earnings of $0.09 per share.Quarterly revenue totaled $121.0 million, modestly exceeding the consensus estimate of $120.55 million and reflecting year-over-year growth of 27%, or 37% when excluding a one-time benefit recorded in 2024. This compares with revenue of $95.3 million in the same quarter a year earlier.Revenue from GeneDx’s core exome and genome testing business rose 32% year over year to $104.0 million, while testing volume increased 34% to 27,761 tests.Adjusted gross margin improved to 71%, compared with 70% in the prior-year period. However, adjusted net income declined to $4.4 million from $17.5 million reported in the fourth quarter of 2024.“The unmet need for early, accurate genomic diagnosis is enormous, and families are waiting far too long for answers,” said Katherine Stueland, President and CEO of GeneDx. “Our team is executing at the highest level, our platform continues to scale, and GeneDx null gives us a compounding data advantage that strengthens with every test we run.”For full-year 2026, GeneDx reaffirmed revenue guidance of $540 million to $555 million, with a midpoint of $547.5 million slightly above the analyst consensus estimate of $543 million. The company expects exome and genome revenue to grow between 33% and 35%, alongside an adjusted gross margin of at least 70%.Full-year 2025 revenue reached $427.5 million, representing 41% growth year over year, while adjusted net income rose to $41.8 million compared with $9.4 million in 2024.GeneDx Holdings Corp stock price

Original: GeneDx Posts Mixed Q4 Performance as Earnings Miss but Revenue Tops Estimates

INSERTING and REPLACING GeneDx Reports Fourth Quarter and Full Year 2025 Financial Results and Reaffirms Guidance for Full Year 2026February 23, 2026 8:07 AM
Business Wire

Reported fourth quarter 2025 revenues of $121.0 million with 32% year-over-year growth in exome and genome test revenue (42% excluding a one-time 2024 benefit)



Accelerated exome and genome volume growth to 34% year-over-year



Reported fourth quarter 2025 adjusted gross margin1 of 71%



Reported fourth quarter 2025 adjusted net income1 of $4.4 million



Reaffirmed full year 2026 guidance of $540 to $555 million in revenue with 33-35% exome and genome growth



GeneDx to host conference call today at 8:30 a.m. ET



Insert the "Software and interpretation services" row in the Volume & Revenue(1) table.


The updated release reads:


GeneDx Reports Fourth Quarter and Full Year 2025 Financial Results and Reaffirms Guidance for Full Year 2026


GeneDx Holdings Corp. (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today reported its financial results for the fourth quarter and full year of 2025.


“The unmet need for early, accurate genomic diagnosis is enormous, and families are waiting far too long for answers. GeneDx is uniquely positioned to deliver for patients, clinicians, and partners — and our results demonstrate that. Our team is executing at the highest level, our platform continues to scale, and GeneDx InfinityTM gives us a compounding data advantage that strengthens with every test we run,” said Katherine Stueland, President and CEO of GeneDx. “The business has never been in a better position for continued growth and success. As we enter 2026, we will layer new growth drivers onto an already powerful foundation — expanding into large, underpenetrated markets where patients are waiting for a diagnosis that GeneDx can provide today.”


Fourth Quarter and Full Year 2025 Financial Results (Unaudited)1,2


Revenues


Fourth quarter 2025:



Revenues grew to $121.0 million, an increase of 27% year-over-year (37% excluding a one-time 2024 benefit).



Exome and genome test revenue grew to $104.0 million, an increase of 32% year-over-year (42% excluding a one-time 2024 benefit).



Full year 2025:



Revenues grew to $427.5 million, an increase of 41% year-over-year (45% excluding a one-time 2024 benefit).



Exome and genome test revenue grew to $360.3 million, an increase of 54% year-over-year (58% excluding a one-time 2024 benefit).



Exome and genome volume


Fourth quarter 2025:



Exome and genome test result volume grew to 27,761, an increase of 34.3% year-over-year.



Exome and genome represented 47% of all test results, up from 38% in the fourth quarter of 2024.



Full year 2025:



Exome and genome test results volume grew to 97,271, an increase of 30.5% year-over-year.



Exome and genome represented 43% of all test results, up from 33% for the full year 2024.



Gross margin


Fourth quarter 2025:



Adjusted gross margin expanded to 71%, up from 70% in the fourth quarter of 2024.


GAAP gross margin was 70%.






Full year 2025:



Adjusted gross margin expanded to 71%, up from 65% for full year 2024.


GAAP gross margin was 70%.






Operating expenses


Fourth quarter 2025:



Adjusted total operating expenses were $81.8 million, representing 68% of revenue in the fourth quarter of 2025, compared to 52% of revenue in the fourth quarter of 2024.


Total GAAP operating expenses were $98.5 million.






Full year 2025:



Adjusted total operating expenses were $263.0 million, an increase of 39% year-over-year.


Total GAAP operating expenses were $311.3 million.






Net income (loss)


Fourth quarter 2025:



Adjusted net income was $4.4 million, compared to $17.5 million in the fourth quarter of 2024.


GAAP net loss was $17.7 million.






Full year 2025:



Adjusted net income was $41.8 million, compared to $9.4 million for full year 2024.


GAAP net loss was $21.0 million.






Full year and fourth quarter 2024 revenues, gross margin and net income, all on both a GAAP and adjusted basis, includes $6.8 million of discrete benefit in connection with a multi-year appeal recovery from a single third-party payor. The fourth quarter 2024 benefit was composed of $5.8 million to exome genome revenues and $1.0 million to other test lines.


Cash position



Cash, cash equivalents, marketable securities and restricted cash was $172.3 million as of December 31, 2025.



Cash flow for the fourth quarter 2025 included:


$5.1 million in net cash generated from ordinary operations; and



$21.1 million in proceeds, net of fees, from the issuance of 147,583 shares of Class A common stock in connection with sales pursuant to our “at-the-market” offering, offset by;



$10.0 million in scheduled payments to service previously recorded settlement liabilities of Legacy Sema4.








(1)






 






Adjusted gross margin, adjusted total operating expenses and adjusted net income/(loss) are non-GAAP financial measures. See appendix for a reconciliation of GAAP to non-GAAP figures presented.








(2)






 






Revenue and adjusted gross margin growth rates in the comparative 2024 period exclude revenue and costs of sales from the exited Legacy Sema4 diagnostic testing business.







GeneDx Full Year 2026 Guidance


For full year 2026 management expects GeneDx to deliver:




Metric






Guidance








Revenue






$540 to $555 million








Growth in exome and genome revenue






33% to 35%








Growth in exome and genome volume






33% to 35%








Adjusted gross margin






At least 70%








Adjusted net income






Positive







Business Highlights


Strategic Expansion & Market Leadership



Launched GeneDx Infinity™: Unveiled the world’s largest and most diverse rare disease dataset – including over 1 million exomes and genomes, more than 2.5 million genetic tests, and over 8 million phenotypic data points – that fuels the #1 genetic test.



Expanded into general pediatrics: Unlocked GeneDx’s largest addressable opportunity to bring genomic testing to the front line of care for more families.


Commended the American Academy of Pediatrics for issuing updated guidance in June 2025, now recommending exome and genome sequencing as first-tier tests for children with global developmental delay or intellectual disability.






Expanded into prenatal diagnostics: Announced GenomeDx Prenatal™, a phenotype-informed, trio-based whole genome sequencing test for pregnancies with fetal anomalies identified via ultrasound, enabling clinicians and expecting families to access actionable genomic insights during one of the most critical moments in pregnancy care.



Launched ultraRapid genome sequencing: Offered accelerated, comprehensive and actionable genomic insights for neonatal and pediatric patients in the NICU and PICU in as soon as 48 hours.



Expanded payer coverage: Secured Medicaid coverage for exome and genome sequencing in 8 new states (including CA, CO, OH), bringing the total states covering exome or genome sequencing in the pediatric outpatient setting to 38 and the total states covering rapid genome sequencing in the neonatal intensive care unit (NICU) to 17.



Strengthened leadership: Positioned the company for the next phase of growth and scale to help more families with the power of our data, AI-driven technology, and clinical expertise.



Named to the 2026 TIME100 Health List: This recognition comes during Rare Disease Month and underscores the growing global acknowledgment of rare disease as a public health priority, as well as the critical role of genomics in accelerating diagnosis, advancing discovery, and improving outcomes for patients and families worldwide.



Innovation & Clinical Leadership



Granted FDA Breakthrough Device designation: Received designation for GeneDx ExomeDx™ and GenomeDx™ associated with causes of life-threatening diseases or genetic disorders to aid in diagnosis of symptomatic patients, underscoring GeneDx’s leadership in genomic medicine and critical role in delivering fast, accurate answers for patients with rare diseases.



Acquired Fabric Genomics: Expanded delivery of genomic insights globally by enabling decentralized interpretation powered GeneDx InfinityTM.



Advanced genomic newborn screening (gNBS): Extended leadership in genomic newborn screening through participation in key programs, including:


Announced participation in the nation’s first multi-state genomic newborn screening initiative, BEACONS (Building Evidence and Collaboration for GenOmics in Nationwide Newborn Screening), which launched with a $14.4 million award from the National Institutes of Health (NIH) to enroll up to 30,000 newborns in as many as 10 states over the next three years.



Announced a partnership with Florida’s Sunshine Genetics Network, the nation’s first state-backed genomic newborn screening program, to offer whole genome sequencing for newborns at select academic medical centers and hospitals.



Sequenced more than 22,000 newborns through the GUARDIAN (Genomic Uniform-screening Against Rare Disease In All Newborns) study, which was recognized as part of JAMA’s annual Research of the Year Roundup.






Announced partnership with Komodo Health: Enhanced GeneDx InfinityTM with real-world patient insights from Komodo’s Healthcare Map® to create the most comprehensive, longitudinal dataset for rare disease.



Unveiled Multiscore: Launched Multiscore, an advanced AI-powered decision support tool that aims to improve diagnostic efficiency, streamlines workflows, and enhances clinical insights by harnessing GeneDx InfinityTM, publicly available data, and the power of artificial intelligence.



Surpassed 1,100 total peer-reviewed studies: Added key publications to the most prolific and clinically impactful research portfolio in rare disease genomics, including the Seqfirst-neo study, a pioneering study conducted in partnership with Seattle Children’s and the University of Washington revealing that widespread use of rapid genome sequencing (rGS) demonstrates that at least 60% of level IV NICU infants should be receiving rGS.



Published data supporting changes to testing protocols: Published data from the SeqFirst study showing that implementing rapid genome sequencing (rWGS) as a first-tier test in pediatric and cardiac intensive care units significantly increases diagnostic rates and reduces time to diagnosis by half.



Webcast and Conference Call Details


GeneDx will host a conference call today, February 23, 2026, at 8:30 a.m. Eastern Time. Investors interested in listening to the conference call are required to register online. A live and archived webcast of the event will be available on the “Events” section of the GeneDx investor relations website at https://ir.genedx.com/.


Non-GAAP Financial Measures


GeneDx believes non-GAAP measures are useful in evaluating its operating performance. GeneDx uses this supplemental information to evaluate its ongoing operations and for internal planning and forecasting purposes. GeneDx believes that non-GAAP financial information, when taken collectively with its GAAP financial information, may be helpful to investors because it provides consistency and comparability with past financial performance. However, non-GAAP financial information is presented for supplemental informational purposes only, has limitations as an analytical tool, and should not be considered in isolation or as a substitute for financial information presented in accordance with GAAP. Reconciliations of non-GAAP financial measures to the most directly comparable financial results as determined in accordance with GAAP are included at the end of this press release following the accompanying financial data. We define non-GAAP financial measures as GAAP measures, excluding certain items such as stock-based compensation expense, depreciation and amortization, restructuring costs, changes in the fair value of financial liabilities, and other expenses that the Company believes are not indicative of its ongoing operations. A reconciliation of non-GAAP guidance measures to corresponding GAAP measures is not available on a forward-looking basis without unreasonable effort due to the uncertainty of expenses that may be incurred in the future. Investors are encouraged to review the related GAAP financial measures and the reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measures and not rely on any single financial measure to evaluate our business.


Forward-Looking Statements


This press release contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995, including statements regarding our future performance and our market opportunity, including our expectations for full year 2026 revenue, exome and genome revenue and test volumes, adjusted gross margin and adjusted net income. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: (i) our ability to implement business plans, goals and forecasts, and identify and realize additional opportunities, (ii) the risk of downturns and a changing regulatory landscape in the highly competitive healthcare industry, (iii) the size and growth of the market in which we operate, and (iv) our ability to pursue our new strategic direction. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the U.S. Securities and Exchange Commission (the “SEC”) on February 20, 2025, our Quarterly Reports on Form 10-Q for the fiscal quarters ended March 31, 2025, June 30, 2025, and September 30, 2025, and other documents filed by us from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and we assume no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. We do not give any assurance that we will achieve our expectations.


About GeneDx


GeneDx’s (Nasdaq: WGS) mission is to empower everyone to live their healthiest life through genomics. GeneDx combines unmatched clinical expertise, advanced technology, and the power of GeneDx Infinity™ – the world’s largest rare disease genomic dataset. This unparalleled foundation powers GeneDx’s ExomeDx™ and GenomeDx™ tests – ranked #1 by expert geneticists and granted FDA Breakthrough Device designation – enabling clinicians to deliver precise, fast, and actionable diagnoses. GeneDx Infinity also fuels discovery for biopharma, with the most powerful AI-driven genomic intelligence. A genomics pioneer over the last 25 years, diagnosing more than 4,800 genetic diseases and publishing more than 1,000 research publications, GeneDx is building the network that will drive the future of genomic precision medicine. For more information, visit genedx.com and connect with us on LinkedIn, Facebook, and Instagram.


Volume & Revenue(1)




 






 






4Q25






 






 






3Q25






 






 






2Q25






 






 






1Q25






 






 






4Q24






 






2025 YTD






 






2024 YTD








Volumes






 






 






 






 






 






 






 






 






 






 






 






 






 








Whole exome, whole genome






 






27,761






 






 






25,702






 






 






23,246






 






 






20,562






 






 






20,676






 






 






97,271






 






 






74,547








Hereditary cancer






 






346






 






 






1,511






 






 






2,677






 






 






2,725






 






 






3,486






 






 






7,259






 






 






20,508








Other panels






 






30,935






 






 






33,003






 






 






31,833






 






 






28,228






 






 






30,115






 






 






123,999






 






 






131,177








Total






 






59,042






 






 






60,216






 






 






57,756






 






 






51,515






 






 






54,277






 






 






228,529






 






 






226,232








 






 






 






 






 






 






 






 






 






 






 






 






 






 








Revenue ($ millions)






 






 






 






 






 






 






 






 






 






 






 






 






 








Whole exome, whole genome






$






104.0






 






$






98.9






 






$






86.0






 






$






71.4






 






$






78.8






 






$






360.3






 






$






233.5








Hereditary cancer






 






0.2






 






 






1.2






 






 






1.8






 






 






2.2






 






 






2.8






 






 






5.4






 






 






15.4








Other panels






 






13.1






 






 






13.4






 






 






12.3






 






 






12.1






 






 






12.3






 






 






50.9






 






 






50.1








Data information






 






2.6






 






 






1.5






 






 






2.0






 






 






1.4






 






 






1.4






 






 






7.5






 






 






3.3







Software and interpretation services


1.1








1.7








0.6








—








—








3.4








—








Total






$






121.0






 






$






116.7






 






$






102.7






 






$






87.1






 






$






95.3






 






$






427.5






 






$






302.3









(1)







Excludes volume and revenue from the exited Legacy Sema4 diagnostic testing business for the fourth quarter and full year 2024.







Unaudited Select Financial Information (in thousands)




 






Three months ended December 31, 2025






 






Three months ended December 31, 2024








 






GeneDx






 






Other(1)






 






Total






 






GeneDx






 






Other(1)






 






Total








Revenue






$119,492






 






$1,497






 






$120,989






 






$95,286






 






$354






 






$95,640








Adjusted cost of services






34,494






 






480






 






34,974






 






28,384






 






—






 






28,384








Adjusted gross profit (loss)






$84,998






 






$1,017






 






$86,015






 






$66,902






 






$354






 






$67,256








Adjusted gross margin %






71.1%






 






 






 






71.1%






 






70.2%






 






 






 






70.3%









 






Year ended December 31, 2025






 






Year ended December 31, 2024








 






GeneDx






 






Other(1)






 






Total






 






GeneDx






 






Other(1)






 






Total








Revenue






$423,088






 






$4,451






 






$427,539






 






$302,293






 






$3,157






 






$305,450








Adjusted cost of services






122,100






 






1,101






 






123,201






 






106,376






 






145






 






106,521








Adjusted gross profit (loss)






$300,988






 






$3,350






 






$304,338






 






$195,917






 






$3,012






 






$198,929








Adjusted gross margin %






71.1%






 






 






 






71.2%






 






64.8%






 






 






 






65.1%









(1)







For the three months and year ended December 31, 2025, Other includes revenue and cost of services from the Fabric Genomics operating segment. For the three months and year ended December 31, 2024, Other includes revenue from the Legacy Sema4 diagnostic testing business.









 






For the three months ended December 31, 2025








 






Reported






 






Depreciation and amortization






 






Stock-based compensation expense






 






Restructuring costs






 






Change in FV of financial liabilities






 






Other(2)






 






Adjusted








Diagnostic test revenue






$






117,286






 






 






$






—






 






 






$






—






 






 






$






—






 






 






$






—






 






 






$






—






 






 






$






117,286






 








Other revenue






 






3,703






 






 






 






—






 






 






 






—






 






 






 






—






 






 






 






—






 






 






 






—






 






 






 






3,703






 








Total revenue






 






120,989






 






 






 






—






 






 






 






—






 






 






 






—






 






 






 






—






 






 






 






—






 






 






 






120,989






 








Cost of services






 






36,721






 






 






 






(1,531






)






 






 






(211






)






 






 






(5






)






 






 






—






 






 






 






—






 






 






 






34,974






 








Gross profit






 






84,268






 






 






 






1,531






 






 






 






211






 






 






 






5






 






 






 






—






 






 






 






—






 






 






 






86,015






 








Gross margin






 






69.6






%






 






 






 






 






 






 






 






 






 






 






 






 






71.1






%








 






 






 






 






 






 






 






 






 






 






 






 






 






 








Research and development






 






24,541






 






 






 






(358






)






 






 






(1,776






)






 






 






(151






)






 






 






—






 






 






 






—






 






 






 






22,256






 








Selling and marketing






 






27,131






 






 






 






(1,333






)






 






 






(1,521






)






 






 






(140






)






 






 






—






 






 






 






—






 






 






 






24,137






 








General and administrative






 






46,831






 






 






 






(3,659






)






 






 






(6,272






)






 






 






(220






)






 






 






—






 






 






 






(1,297






)






 






 






35,383






 








 






 






 






 






 






 






 






 






 






 






 






 






 






 








(Loss) income from operations






 






(14,235






)






 






 






6,881






 






 






 






9,780






 






 






 






516






 






 






 






—






 






 






 






1,297






 






 






 






4,239






 








 






 






 






 






 






 






 






 






 






 






 






 






 






 








Interest expense, net






 






(520






)






 






 






—






 






 






 






—






 






 






 






—






 






 






 






—






 






 






 






520






 






 






 






—






 








Other (expense) income, net






 






(3,475






)






 






 






—






 






 






 






—






 






 






 






—






 






 






 






(1,116






)






 






 






4,752






 






 






 






161






 








Income tax benefit






 






564






 






 






 






—






 






 






 






—






 






 






 






—






 






 






 






—






 






 






 






(564






)






 






 






—






 








Net (loss) income






$






(17,666






)






 






$






6,881






 






 






$






9,780






 






 






$






516






 






 






$






(1,116






)






 






$






6,005






 






 






$






4,400






 








 






 






 






 






 






 






 






 






 






 






 






 






 






 








Basic (loss) earnings per share(1)






$






(0.61






)






 






 






 






 






 






 






 






 






 






 






 






$






0.15






 








Diluted (loss) earnings per share(1)






$






(0.61






)






 






 






 






 






 






 






 






 






 






 






 






$






0.14






 









 






For the three months ended December 31, 2024








 






Reported






 






Depreciation and amortization






 






Stock-based compensation expense






 






Restructuring costs






 






Change in FV of financial liabilities






 






Other(2)






 






Adjusted








Diagnostic test revenue






$






94,196






 






 






$






—






 






 






$






—






 






 






$






—






 






 






$






—






 






$






—






 






 






$






94,196






 








Other revenue






 






1,444






 






 






 






—






 






 






 






—






 






 






 






—






 






 






 






—






 






 






—






 






 






 






1,444






 








Total revenue






 






95,640






 






 






 






—






 






 






 






—






 






 






 






—






 






 






 






—






 






 






—






 






 






 






95,640






 








Cost of services






 






29,435






 






 






 






(928






)






 






 






(123






)






 






 






—






 






 






 






—






 






 






—






 






 






 






28,384






 








Gross profit






 






66,205






 






 






 






928






 






 






 






123






 






 






 






—






 






 






 






—






 






 






—






 






 






 






67,256






 








Gross margin






 






69.2






%






 






 






 






 






 






 






 






 






 






 






 






 






70.3






%








 






 






 






 






 






 






 






 






 






 






 






 






 






 








Research and development






 






11,588






 






 






 






(294






)






 






 






(495






)






 






 






(13






)






 






 






—






 






 






—






 






 






 






10,786






 








Selling and marketing






 






17,676






 






 






 






(1,225






)






 






 






(347






)






 






 






(30






)






 






 






—






 






 






—






 






 






 






16,074






 








General and administrative






 






28,135






 






 






 






(3,111






)






 






 






(1,880






)






 






 






(249






)






 






 






—






 






 






—






 






 






 






22,895






 








 






 






 






 






 






 






 






 






 






 






 






 






 






 








Income from operations






 






8,806






 






 






 






5,558






 






 






 






2,845






 






 






 






292






 






 






 






—






 






 






—






 






 






 






17,501






 








 






 






 






 






 






 






 






 






 






 






 






 






 






 








Interest expense, net






 






(698






)






 






 






—






 






 






 






—






 






 






 






—






 






 






 






—






 






 






698






 






 






 






—






 








Other (expense) income, net






 






(2,694






)






 






 






—






 






 






 






—






 






 






 






—






 






 






 






1,980






 






 






666






 






 






 






(48






)








Income tax benefit






 






24






 






 






 






—






 






 






 






—






 






 






 






—






 






 






 






—






 






 






(24






)






 






 






—






 








Net income






$






5,438






 






 






$






5,558






 






 






$






2,845






 






 






$






292






 






 






$






1,980






 






$






1,340






 






 






$






17,453






 








 






 






 






 






 






 






 






 






 






 






 






 






 






 








Basic earnings per share(1)






$






0.20






 






 






 






 






 






 






 






 






 






 






 






 






$






0.63






 








Diluted earnings per share(1)






$






0.18






 






 






 






 






 






 






 






 






 






 






 






 






$






0.59






 









(1)






 






Basic and diluted (loss) earnings per share are calculated based on 29,045,526 and 30,365,730 weighted-average shares outstanding for the three months ended December 31, 2025, respectively, and 27,776,757 and 29,595,716 weighted-average shares outstanding for the three months ended December 31, 2024, respectively.








(2)






 






Other represents interest expense, net, and income tax benefit for all periods presented. For the three months ended December 31, 2025, Other includes legal costs and a reserve for a certain litigation matter. For the three months ended December 31, 2024, Other includes legal costs related to a legal settlement.









 






For the year ended December 31, 2025








 






Reported






 






Depreciation and amortization






 






Stock-based compensation expense






 






Restructuring costs






 






Change in FV of financial liabilities






 






Other(2)






 






Adjusted








Diagnostic test revenue






$






416,668






 






 






$






—






 






 






$






—






 






 






$






—






 






 






$






—






 






$






—






 






 






$






416,668






 








Other revenue






 






10,871






 






 






 






—






 






 






 






—






 






 






 






—






 






 






 






—






 






 






—






 






 






 






10,871






 








Total revenue






 






427,539






 






 






 






—






 






 






 






—






 






 






 






—






 






 






 






—






 






 






—






 






 






 






427,539






 








Cost of services






 






129,366






 






 






 






(5,369






)






 






 






(791






)






 






 






(5






)






 






 






—






 






 






—






 






 






 






123,201






 








Gross profit






 






298,173






 






 






 






5,369






 






 






 






791






 






 






 






5






 






 






 






—






 






 






—






 






 






 






304,338






 








Gross margin






 






69.7






%






 






 






 






 






 






 






 






 






 






 






 






 






71.2






%








 






 






 






 






 






 






 






 






 






 






 






 






 






 








Research and development






 






72,026






 






 






 






(1,181






)






 






 






(5,366






)






 






 






17






 






 






 






—






 






 






—






 






 






 






65,496






 








Selling and marketing






 






88,405






 






 






 






(5,190






)






 






 






(5,009






)






 






 






(292






)






 






 






—






 






 






—






 






 






 






77,914






 








General and administrative






 






150,819






 






 






 






(13,484






)






 






 






(20,996






)






 






 






(995






)






 






 






—






 






 






4,287






 






 






 






119,631






 








 






 






 






 






 






 






 






 






 






 






 






 






 






 








(Loss) income from operations






 






(13,077






)






 






 






25,224






 






 






 






32,162






 






 






 






1,275






 






 






 






—






 






 






(4,287






)






 






 






41,297






 








 






 






 






 






 






 






 






 






 






 






 






 






 






 








Interest expense, net






 






(2,539






)






 






 






—






 






 






 






—






 






 






 






—






 






 






 






—






 






 






2,539






 






 






 






—






 








Other (expense) income, net






 






(5,521






)






 






 






—






 






 






 






—






 






 






 






—






 






 






 






1,204






 






 






4,829






 






 






 






512






 








Income tax benefit






 






116






 






 






 






—






 






 






 






—






 






 






 






—






 






 






 






—






 






 






(116






)






 






 






—






 








Net (loss) income






$






(21,021






)






 






$






25,224






 






 






$






32,162






 






 






$






1,275






 






 






$






1,204






 






$






2,965






 






 






$






41,809






 








 






 






 






 






 






 






 






 






 






 






 






 






 






 








Basic (loss) earnings per share(1)






$






(0.73






)






 






 






 






 






 






 






 






 






 






 






 






$






1.46






 








Diluted (loss) earnings per share(1)






$






(0.73






)






 






 






 






 






 






 






 






 






 






 






 






$






1.40






 









 






For the year ended December 31, 2024








 






Reported






 






Depreciation and amortization






 






Stock-based compensation expense






 






Restructuring costs






 






Change in FV of financial liabilities






 






Other(2)






 






Adjusted








Diagnostic test revenue






$






302,157






 






 






$






—






 






 






$






—






 






 






$






—






 






 






$






—






 






$






—






 






 






$






302,157






 








Other revenue






 






3,293






 






 






 






—






 






 






 






—






 






 






 






—






 






 






 






—






 






 






—






 






 






 






3,293






 








Total revenue






 






305,450






 






 






 






—






 






 






 






—






 






 






 






—






 






 






 






—






 






 






—






 






 






 






305,450






 








Cost of services






 






111,053






 






 






 






(4,047






)






 






 






(431






)






 






 






(54






)






 






 






—






 






 






—






 






 






 






106,521






 








Gross profit






 






194,397






 






 






 






4,047






 






 






 






431






 






 






 






54






 






 






 






—






 






 






—






 






 






 






198,929






 








Gross margin






 






63.6






%






 






 






 






 






 






 






 






 






 






 






 






 






65.1






%








 






 






 






 






 






 






 






 






 






 






 






 






 






 








Research and development






 






45,722






 






 






 






(923






)






 






 






(1,192






)






 






 






(151






)






 






 






—






 






 






—






 






 






 






43,456






 








Selling and marketing






 






67,371






 






 






 






(4,900






)






 






 






(1,089






)






 






 






(548






)






 






 






—






 






 






—






 






 






 






60,834






 








General and administrative






 






104,517






 






 






 






(12,083






)






 






 






(6,426






)






 






 






(999






)






 






 






—






 






 






—






 






 






 






85,009






 








 






 






 






 






 






 






 






 






 






 






 






 






 






 








(Loss) income from operations






 






(23,213






)






 






 






21,953






 






 






 






9,138






 






 






 






1,752






 






 






 






—






 






 






—






 






 






 






9,630






 








 






 






 






 






 






 






 






 






 






 






 






 






 






 








Interest expense, net






 






(3,032






)






 






 






—






 






 






 






—






 






 






 






—






 






 






 






—






 






 






3,032






 






 






 






—






 








Other (expense) income, net






 






(26,384






)






 






 






—






 






 






 






—






 






 






 






—






 






 






 






13,370






 






 






12,789






 






 






 






(225






)








Income tax benefit






 






343






 






 






 






—






 






 






 






—






 






 






 






—






 






 






 






—






 






 






(343






)






 






 






—






 








Net (loss) income






$






(52,286






)






 






$






21,953






 






 






$






9,138






 






 






$






1,752






 






 






$






13,370






 






$






15,478






 






 






$






9,405






 








 






 






 






 






 






 






 






 






 






 






 






 






 






 








Basic (loss) earnings per share(1)






$






(1.94






)






 






 






 






 






 






 






 






 






 






 






 






$






0.35






 








Diluted (loss) earnings per share(1)






$






(1.94






)






 






 






 






 






 






 






 






 






 






 






 






$






0.34






 









(1)






 






Basic and diluted (loss) earnings per share are calculated based on 28,641,734 and 29,835,437 weighted-average shares outstanding for the year ended December 31, 2025, respectively, and 26,891,213 and 27,368,912 weighted-average shares outstanding for the year ended December 31, 2024, respectively.








(2)






 






Other represents interest expense, net, and income tax benefit for all periods presented. For the year ended December 31, 2025, Other includes transaction costs related to the acquisition of Fabric Genomics, legal costs and a reserve for a certain litigation matter, and a sales-and-use tax refund. For the year ended December 31, 2024, Other includes reserves net of insurance for a certain litigation matter.









GeneDx Holdings Corp.




Consolidated Balance Sheets




(in thousands, except share and per share amounts)








 



 






December 31,








 






 






2025






 






 






 






2024






 








Assets:






 






 






 








Current assets:






 






 






 








Cash and cash equivalents






$






104,997






 






 






$






85,212






 








Marketable securities






 






66,285






 






 






 






55,973






 








Accounts receivable






 






74,370






 






 






 






37,629






 








Inventory, net






 






13,951






 






 






 






10,650






 








Prepaid expenses and other current assets






 






8,685






 






 






 






8,504






 








Total current assets






 






268,288






 






 






 






197,968






 








Operating lease right-of-use assets






 






23,412






 






 






 






25,613






 








Property and equipment, net






 






45,693






 






 






 






32,893






 








Goodwill






 






13,520






 






 






 






—






 








Intangible assets, net






 






168,481






 






 






 






158,600






 








Other assets (1)






 






4,316






 






 






 






4,306






 








Total assets






$






523,710






 






 






$






419,380






 








Liabilities and Stockholders’ Equity:






 






 






 








Current liabilities:






 






 






 








Accounts payable and accrued expenses






$






57,645






 






 






$






30,983






 








Short-term lease liabilities






 






4,404






 






 






 






3,336






 








Other current liabilities






 






46,859






 






 






 






20,498






 








Total current liabilities






 






108,908






 






 






 






54,817






 








Long-term debt, net of current portion






 






48,176






 






 






 






51,913






 








Long-term lease liabilities






 






56,046






 






 






 






60,919






 








Other liabilities






 






1,641






 






 






 






5,519






 








Deferred taxes






 






757






 






 






 






965






 








Total liabilities






 






215,528






 






 






 






174,133






 








Stockholders’ Equity:






 






 






 








Preferred stock






 






—






 






 






 






—






 








Class A common stock






 






3






 






 






 






2






 








Additional paid-in capital






 






1,680,738






 






 






 






1,596,889






 








Accumulated deficit






 






(1,373,495






)






 






 






(1,352,474






)








Accumulated other comprehensive income






 






936






 






 






 






830






 








Total stockholders’ equity






 






308,182






 






 






 






245,247






 








Total liabilities and stockholders’ equity






$






523,710






 






 






$






419,380






 









(1)







Other assets includes $1.0 million of restricted cash as of both December 31, 2025 and 2024.









GeneDx Holdings Corp.




Consolidated Statements of Operations




(in thousands, except share and per share amounts)








 



 






Year ended December 31,








 






 






2025






 






 






 






2024






 








Revenue






 






 






 








Diagnostic test revenue






$






416,668






 






 






$






302,157






 








Other revenue






 






10,871






 






 






 






3,293






 








Total revenue






 






427,539






 






 






 






305,450






 








Cost of services






 






129,366






 






 






 






111,053






 








Gross profit






 






298,173






 






 






 






194,397






 








Research and development






 






72,026






 






 






 






45,722






 








Selling and marketing






 






88,405






 






 






 






67,371






 








General and administrative






 






150,819






 






 






 






104,517






 








Loss from operations






 






(13,077






)






 






 






(23,213






)








 






 






 






 








Non-operating (expenses) income, net






 






 






 








Change in fair value of financial liabilities






 






(1,204






)






 






 






(13,370






)








Interest (expense) income, net






 






(2,539






)






 






 






(3,032






)








Other (expense) income, net






 






(4,317






)






 






 






(13,014






)








Total non-operating (expense) income, net






 






(8,060






)






 






 






(29,416






)








Loss before income taxes






 






(21,137






)






 






 






(52,629






)








Income tax benefit






 






116






 






 






 






343






 








Net loss






$






(21,021






)






 






$






(52,286






)








 






 






 






 








Basic and diluted weighted average shares outstanding of Class A common stock






 






28,641,734






 






 






 






26,891,213






 








Basic and diluted net loss per share, Class A common stock






$






(0.73






)






 






$






(1.94






)









GeneDx Holdings Corp.




Consolidated Statements of Cash Flows




(in thousands)








 



 






Year Ended December 31,








 






 






2025






 






 






 






2024






 








Operating activities






 






 






 








Net loss






$






(21,021






)






 






$






(52,286






)








Adjustments to reconcile net loss to net cash used in operating activities:






 






 






 








Depreciation and amortization expense






 






25,224






 






 






 






21,953






 








Stock-based compensation expense






 






32,162






 






 






 






9,138






 








Change in fair value of financial liabilities






 






1,204






 






 






 






13,370






 








Provision for excess and obsolete inventory






 






135






 






 






 






180






 








Legal reserves






 






5,560






 






 






 






—






 








Change in third party payor reserves






 






2,449






 






 






 






607






 








Other






 






3,163






 






 






 






3,287






 








Change in operating assets and liabilities:






 






 






 








Accounts receivable






 






(36,231






)






 






 






(5,180






)








Inventory






 






(3,436






)






 






 






(2,585






)








Accounts payable and accrued expenses






 






12,100






 






 






 






(20,524






)








Other assets and liabilities






 






11,970






 






 






 






3,544






 








Net cash provided by (used in) operating activities






 






33,279






 






 






 






(28,496






)








Investing activities






 






 






 








Acquisition of business, net of cash acquired






 






(32,856






)






 






 






—






 








Purchases of marketable securities






 






(55,676






)






 






 






(66,302






)








Proceeds from sales of marketable securities






 






2,062






 






 






 






601






 








Proceeds from maturities of marketable securities






 






43,970






 






 






 






41,060






 








Purchases of property and equipment






 






(19,017






)






 






 






(5,491






)








Net cash used in investing activities






 






(61,517






)






 






 






(30,132






)








Financing activities






 






 






 








Proceeds from offerings, net of issuance costs






 






46,704






 






 






 






46,496






 








Proceeds from issuance of stock pursuant to employee stock purchase plan






 






2,961






 






 






 






497






 








Exercise of stock options






 






2,022






 






 






 






394






 








Long-term debt principal payments






 






(1,211






)






 






 






(497






)








Finance lease payoff and principal payments






 






(2,451






)






 






 






(2,728






)








Net cash provided by financing activities






 






48,025






 






 






 






44,162






 








Net increase (decrease) in cash, cash equivalents and restricted cash






 






19,787






 






 






 






(14,466






)








Cash, cash equivalents and restricted cash, at beginning of year






 






86,202






 






 






 






100,668






 








Cash, cash equivalents and restricted cash, at end of year (1)






$






105,989






 






 






$






86,202






 









(1)







Cash, cash equivalents and restricted cash at December 31, 2025 excludes marketable securities of $66.3 million.







 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260223454462/en/
Investor Relations Contact:

Investors@GeneDx.com


Media Contact:

Press@GeneDx.com


Original: INSERTING and REPLACING GeneDx Reports Fourth Quarter and Full Year 2025 Financial Results and Reaffirms Guidance for Full Year 2026